Drugs / CS-1103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06316973 | Feb → May 2024 | substance abuse | Clear Scientific, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07459166 Comparator | May → Jul 2026 overdue | acute opioid poisoning | Clear Scientific, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06721494 Comparator | Feb → Sep 2026 overdue | substance abuse | Clear Scientific, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-1103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06721494 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT06316973 ↗ |